Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076568 | 0.83 | KMT2A (0.49) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10053133 | 0.82 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL413698 | 0.81 | SMN1; SMN2 (0.47) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19633808 | 0.81 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1691249 | 0.80 | L3MBTL1 (0.43) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL8337648 | 0.80 | ALDH1A1 (0.57) | SMN1; SMN2KDM4EALDH1A1MAPTLTA4H | |
| SCHEMBL13091242 | 0.78 | CYP4F2 (0.53) | F10 | |
| SCHEMBL10053125 | 0.77 | CHRNB2 (0.47) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12545915 | 0.76 | F10 (0.42) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10289795 | 0.76 | ALOX5 (0.52) | SMN1; SMN2LMNAF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106031-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106031-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | ANACOR PHARMACEUTICALS (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | ANACOR PHARMACEUTICALS (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | GAA, BTD, MANBA | MEN1 663/4885KMT2A 2279/4885SMN1; SMN2 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.